keyword
MENU ▼
Read by QxMD icon Read
search

teriparatide

keyword
https://www.readbyqxmd.com/read/28727344/-to-where-and-until-when-handle-the-osteoporosis
#1
Brigitte Uebelhart, Serge Ferrari
Estrogen replacement therapy, selective modulators of the estrogen receptor (SERMs), bisphophonates and denosumab are antiresorptive therapies which can be used for several years. Teriparatide is still the only bone forming agent available, its use is limited to 24 months. Except the absence of new fragility fractures, there is no well defined target in the treatment of osteoporosis. Nevertheless persistence of high fracture risk (prevalent fractures and/or low BMD) on therapy indicates to maintain or intensify the treatment...
April 19, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28721134/osteoporosis-in-men
#2
REVIEW
Waldemar Misiorowski
Osteoporotic fractures are the leading cause of morbidity and mortality among aging men. 30% of all hip fractures occur in men, and mortality resulting from not only the hip fracture, but also the spine and other major osteoporotic fractures, is significantly higher in men than in women. As in women, hypogonadism is the best documented risk factor for developing osteoporosis in men. In older men, testosterone levels are negatively correlated with the risk of fractures, and it seems that this age-related testosterone deficiency should not be considered as one of the many causes of secondary osteoporosis, rather one of the major and most important mechanisms of senile osteoporosis...
June 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28714038/one-and-two-year-persistence-with-different-anti-osteoporosis-medications-a-retrospective-cohort-study
#3
C Reyes, C Tebe, D Martinez-Laguna, M S Ali, A Soria-Castro, C Carbonell, D Prieto-Alhambra
Adherence to anti-osteoporosis medications is poor. We carried out a cohort study using a real-world population database to estimate the persistence of anti-osteoporosis drugs. Unadjusted 2-year persistence ranged from 10.3 to 45.4%. Denosumab users had a 40% lower risk of discontinuation at 2 years compared to alendronate users. PURPOSE: The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications. METHODS: This is a retrospective cohort using data from anonymised records and dispensation data ( www...
July 16, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28706360/osteoporosis-prevention-and-management
#4
Muralidhar V Pai
Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference population, is the most common bone disease in humans affecting both sexes and all races. It's a silent killer affecting the quality of life due to fractures and postural changes. In osteoporosis there is an imbalance between bone formation and bone resorption in favor of latter. Preventive measures and treatments are available to combat this evil. Counseling is the integral part of prevention as well as treatment of osteoporosis...
August 2017: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/28699789/real-world-effectiveness-of-daily-teriparatide-in-japanese-patients-with-osteoporosis-at-high-risk-for-fracture-final-results-from-the-24-month-japan-fracture-observational-study-jfos
#5
Satoshi Soen, Saeko Fujiwara, Ryoichi Takayanagi, Kenta Kajimoto, Mika Tsujimoto, Shuichi Kimura, Masayo Sato, John H Krege, Hiroyuki Enomoto
OBJECTIVE: The Japan Fracture Observational Study (JFOS), a prospective observational study, investigated the real-world effectiveness of daily teriparatide to reduce clinical fracture risk in osteoporotic patients. METHODS: In routine clinical practice, Japanese patients initiated on teriparatide 20 μg/day by subcutaneous injection were enrolled. The primary endpoint was the rate of clinical fractures at 6-month intervals over 24 months. Bone mineral density (BMD), procollagen type 1 aminoterminal propeptide (P1NP), back pain, and health-related quality of life (HRQoL) information was collected...
July 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28690911/two-year-clinical-outcome-of-denosumab-treatment-alone-and-in-combination-with-teriparatide-in-japanese-treatment-naive-postmenopausal-osteoporotic-women
#6
Yukio Nakamura, Takako Suzuki, Mikio Kamimura, Shota Ikegami, Kohei Murakami, Shigeharu Uchiyama, Akira Taguchi, Hiroyuki Kato
This randomized prospective study aimed to evaluate the clinical outcome of denosumab treatment alone and in combination with teriparatide in treatment-naive postmenopausal Japanese female patients with osteoporosis. Thirty patients were randomly assigned to two groups: (1) denosumab group (denosumab alone, n=13); and (2) combination group (denosumab+teriparatide, n=17). Serum bone-specific alkaline phosphatase (BAP), serum tartrate-resistant acid phosphatase (TRACP)-5b, urinary cross-linked N-terminal telopeptides of type I collagen (NTX), and bone mineral density (BMD) of L1-4 lumbar vertebrae (L-BMD) and bilateral total hips (H-BMD) were determined at the first visit and at various time points up to 24 months post-treatment to determine percentage changes...
2017: Bone Research
https://www.readbyqxmd.com/read/28690468/bone-mineral-density-response-from-teriparatide-in-patients-with-osteoporosis
#7
So-Young Kim, Meng Zhang, Richard Bockman
BACKGROUND: A review of data from large clinical trials reported more than 90% of subjects significantly improved their bone mineral density (BMD) at the lumbar spine (LS) with teriparatide (TPTD) (bone 39:1268-1275, 1). However, our clinical experience suggests that many patients may be non-responders, raising questions as to the true efficacy of TPTD in improving BMD in osteoporotic patients. QUESTIONS/PURPOSES: The purpose of the study is to determine the rate of improvement in BMD following 18-24 months of teriparatide (TPTD) in patients with osteoporosis within an orthopedic hospital setting...
July 2017: HSS Journal: the Musculoskeletal Journal of Hospital for Special Surgery
https://www.readbyqxmd.com/read/28689769/osteoporosis-treatment-recent-developments-and-ongoing-challenges
#8
REVIEW
Sundeep Khosla, Lorenz C Hofbauer
Osteoporosis is an enormous and growing public health problem. Once considered an inevitable consequence of ageing, it is now eminently preventable and treatable. Ironically, despite tremendous therapeutic advances, there is an increasing treatment gap for patients at high fracture risk. In this Series paper, we trace the evolution of drug therapy for osteoporosis, which began in the 1940s with the demonstration by Fuller Albright that treatment with oestrogen could reverse the negative calcium balance that developed in women after menopause or oophorectomy...
July 6, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28680788/profile-of-abaloparatide-and-its-potential-in-the-treatment-of-postmenopausal-osteoporosis
#9
REVIEW
Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa
Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis. This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This paper is based on clinical trials and a PubMed search. Search terms used were "abaloparatide", "BA058", and "PTHrP". This review outlines the effects of this anabolic PTHR1 activator, which increases bone mineral density in patients at high risk for osteoporosis...
May 31, 2017: Curēus
https://www.readbyqxmd.com/read/28667435/using-osteoporosis-therapies-in-combination
#10
REVIEW
Michael R McClung
PURPOSE OF REVIEW: The objective of this review is to update evidence regarding the use of osteoporosis drugs in sequence or in combination to optimize increases in bone mass and strength. RECENT FINDINGS: Simultaneous use of denosumab plus teriparatide produces larger increases in BMD than does monotherapy. The use of bisphosphonates or denosumab after teriparatide results in progressive gains in BMD. When switching from bisphosphonates and especially denosumab to teriparatide, an overlap of 6-12 months may prevent the transient loss of BMD in cortical sites...
June 30, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28653616/head-to-head-comparisons-of-bisphosphonates-and-teriparatide-in-osteoporosis-a-meta-analysis
#11
Chun-Lin Liu, Han-Chung Lee, Chun-Chung Chen, Der-Yang Cho
PURPOSE: This meta-analysis aimed to compare the efficacy and safety of teriparatide vs. bisphosphonates in the management of osteoporosis. METHODS: A total of 1,967 patients from eight randomized controlled trials were analyzed; outcomes included bone mineral density (BMD) of the femoral neck, total hip and lumbar spine, vertebral and nonvertebral fractures and any adverse event. A subgroup analysis of treatment effectiveness was performed according to the etiology of osteoporosis; i...
June 26, 2017: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/28631217/24-month-open-label-teriparatide-once-weekly-efficacy-research-trial-examining-bone-mineral-density-in-subjects-with-primary-osteoporosis-and-high-fracture-risk
#12
Toshitsugu Sugimoto, Masataka Shiraki, Masao Fukunaga, Hiroshi Hagino, Teruki Sone, Tetsuo Nakano, Hideaki Kishimoto, Masako Ito, Hideki Yoshikawa, Mitsukazu Kishida, Chika Irie, Toshitaka Nakamura
INTRODUCTION: To clarify the additional efficacy and safety benefits of 24 months' treatment with the once-weekly formulation of teriparatide, which is currently used for 72 weeks. METHODS: This was a multicenter, open-label, single-arm study conducted in Japan. Subjects who were 65 years or older with prevalent vertebral fractures received once-weekly subcutaneous injection of 56.5 μg teriparatide for 24 months. The main outcome measure was percentage change from baseline in lumbar (L2-L4) BMD measured by dual-energy X-ray absorptiometry...
July 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28630836/teriparatide-treatment-improved-loosening-of-cementless-total-knee-arthroplasty-a-case-report
#13
Takashi Suzuki, Keinosuke Ryu, Kei Kojima, Shu Saito, Hiroshi Nagaoka, Yasuaki Tokuhashi
INTRODUCTION: Along with the increase of osteoporotic patients in an aging society, complications in surgeries associated with osteoporosis are also increasing. In cementless total knee arthroplasty (TKA), poor primary stability and subsequent initial loosening of the implant may be seen. CASE REPORT: The patient, a 75-year-old Asian woman with a history of osteoporosis, underwent cementless TKA. Knee radiography at 5 weeks postoperatively showed radiolucent lines outlined beneath the tibial tray and around the stem...
January 2017: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/28629610/a-model-for-assessing-the-clinical-and-economic-benefits-of-bone-forming-agents-for-reducing-fractures-in-postmenopausal-women-at-high-near-term-risk-of-osteoporotic-fracture
#14
Claire E O'Hanlon, Anju Parthan, Morgan Kruse, Shannon Cartier, Bjorn Stollenwerk, Yawen Jiang, John P Caloyeras, Daria B Crittenden, Richard Barron
PURPOSE: The goal of this study was to assess and compare the potential clinical and economic value of emerging bone-forming agents using the only currently available agent, teriparatide, as a reference case in patients at high, near-term (imminent, 1- to 2-year) risk of osteoporotic fractures, extending to a lifetime horizon with sequenced antiresorptive agents for maintenance treatment. METHODS: Analyses were performed by using a Markov cohort model accounting for time-specific fracture protection effects of bone-forming agents followed by antiresorptive treatment with denosumab...
June 16, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28625337/osteogenesis-imperfecta-a-clinical-update
#15
Symeon Tournis, Anastasia D Dede
Osteogenesis imperfecta (OI) is the most common inherited form of bone fragility and includes a heterogenous group of genetic disorders which most commonly result from defects associated with type 1 collagen. 85%-90% of cases are inherited in an autosomal dominant manner and are caused by mutations in the COL1A1 and COL1A2 genes, leading to quantitative or qualitative defects in type 1 collagen. In the last decade, defects in several other proteins involved in the normal processing of type 1 collagen have been described...
June 8, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28624340/effects-of-teriparatide-denosumab-or-both-on-spine-trabecular-microarchitecture-in-data-switch-a-randomized-controlled-trial
#16
Joy N Tsai, Linda A Jiang, Hang Lee, Didier Hans, Benjamin Z Leder
In postmenopausal women, 2 yr of combined teriparatide and denosumab increases bone mineral density more than either drug alone, and switching from either combination or teriparatide to denosumab for an additional 2 yr further increases bone mineral density. Conversely, switching from denosumab to teriparatide results in transient bone loss. The effects of these interventions on spine microarchitecture are unknown. In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both...
June 14, 2017: Journal of Clinical Densitometry
https://www.readbyqxmd.com/read/28614613/population-pharmacokinetic-and-exposure-response-analysis-of-weekly-teriparatide-in-osteoporosis-patients
#17
Atsushi Ose, Masashi Serada, Keiko Yamashita, Kazuyuki Tsurui, Yusuke Tanigawara
Teriparatide is a potent therapeutic agent for the treatment of osteoporosis. One of the aims of this analysis was to develop a population pharmacokinetic (PPK) model to understand the pharmacokinetic characteristics of the once-weekly formulation of teriparatide. Another aim was to develop an exposure-response model to describe the relationship between change in bone mineral density (BMD) and teriparatide exposure after weekly subcutaneous administration. The PPK analysis showed that apparent total body clearance was significantly influenced by estimated creatinine clearance and the presence of osteoporosis...
June 14, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28608571/effects-of-denosumab-and-teriparatide-transitions-on-bone-microarchitecture-and-estimated-strength-the-data-switch-hr-pqct-study
#18
Tsai J N, Nishiyama K K, Lin D, Yuan A, Lee H, Bouxsein M L, Leder B Z
In postmenopausal osteoporosis, switching from teriparatide to denosumab results in continued bone mineral density (BMD) gains whereas switching from denosumab to teriparatide results in BMD loss. To assess the effects of these transitions on bone microarchitecture and strength, we performed high-resolution peripheral QCT (HR-pQCT) at the distal tibia and radius in postmenopausal osteoporotic women who received 24-months of teriparatide 20-mcg daily followed by 24-months of denosumab 60-mg every 6 months, 24-months of denosumab followed by 24-months of teriparatide, or 24-months of both medications followed by 24-months of denosumab...
June 13, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28589205/effects-of-teriparatide-and-sequential-minodronate-on-lumbar-spine-bone-mineral-density-and-microarchitecture-in-osteoporosis
#19
Daichi Miyaoka, Yasuo Imanishi, Masaya Ohara, Noriyuki Hayashi, Yuki Nagata, Shinsuke Yamada, Katsuhito Mori, Masanori Emoto, Masaaki Inaba
The trabecular bone score (TBS) is a new surrogate for trabecular bone microarchitecture assessment, independent of bone mineral density (BMD), calculated from pixel gray-level variations in the lumbar spine (LS) dual-energy X-ray absorptiometry (DXA) image. Although Teriparatide (TPTD) increased LS-BMD as well as TBS in 2 years, the precise time-course of these parameters was not well known. The aim of this study was to determine the changes in LS-BMD and the TBS in osteoporotic patients treated with TPTD, followed by minodronate (MINO)...
June 6, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28585410/2017-american-college-of-rheumatology-guideline-for-the-prevention-and-treatment-of-glucocorticoid-induced-osteoporosis
#20
Lenore Buckley, Gordon Guyatt, Howard A Fink, Michael Cannon, Jennifer Grossman, Karen E Hansen, Mary Beth Humphrey, Nancy E Lane, Marina Magrey, Marc Miller, Lake Morrison, Madhumathi Rao, Angela Byun Robinson, Sumona Saha, Susan Wolver, Raveendhara R Bannuru, Elizaveta Vaysbrot, Mikala Osani, Marat Turgunbaev, Amy S Miller, Timothy Mcalindon
OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength...
June 6, 2017: Arthritis Care & Research
keyword
keyword
112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"